摘要
胆管癌(简称CCA)约占消化道肿瘤的3%,是一种发病率相对较低的罕见病。在此,我们首先通过生物信息学预测在 CCA 组织以及细胞系中发现了 microRNA-23a-3p(缩写为 miR-23a-3p)的过表达。接下来,通过在 HUCCT1 细胞中进行 miR-23a-3p 敲低系统和在 RBE 细胞中进行 miR-23a-3p 过表达系统,我们研究了 miR-23a-3p 的生物学效应。根据我们的发现,抑制 miR-23a-3p 能够通过集落形成、CCK-8 以及 EdU 检测来防止癌细胞增殖。此外,通过transwell试验和伤口愈合试验检查细胞的侵袭和迁移能力。动物研究进一步证实,敲低 miR-23a-3p 可减缓肿瘤生长和肺转移。此外,我们通过一系列测定鉴定了胆管癌细胞通过外泌体转移 miR-23a-3p。功能实验已经证实,外泌体 miR-23a-3p 可以作为促癌基因,有利于癌细胞的生长和转移。此外,我们发现 Dynamin3(缩写为 DNM3)原来是 miR-23a-3p 的靶标,而 DNM3 在胆管癌中下调。击倒 DNM3 加速了癌细胞的发展。总的来说,我们的研究结果首先指出外泌体 miR-23a-3p 通过与 DNM3 的相互作用有利于胆管癌的进展,这为癌症治疗提供了潜在的证据。功能实验已经证实,外泌体 miR-23a-3p 可以作为促癌基因,有利于癌细胞的生长和转移。此外,我们发现 Dynamin3(缩写为 DNM3)原来是 miR-23a-3p 的靶标,而 DNM3 在胆管癌中下调。击倒 DNM3 加速了癌细胞的发展。总的来说,我们的研究结果首先指出外泌体 miR-23a-3p 通过与 DNM3 的相互作用有利于胆管癌的进展,这为癌症治疗提供了潜在的证据。功能实验已经证实,外泌体 miR-23a-3p 可以作为促癌基因,有利于癌细胞的生长和转移。此外,我们发现 Dynamin3(缩写为 DNM3)原来是 miR-23a-3p 的靶标,而 DNM3 在胆管癌中下调。击倒 DNM3 加速了癌细胞的发展。总的来说,我们的研究结果首先指出外泌体 miR-23a-3p 通过与 DNM3 的相互作用有利于胆管癌的进展,这为癌症治疗提供了潜在的证据。
"点击查看英文标题和摘要"
Exosomal microRNA-23a-3p contributes to the progression of cholangiocarcinoma by interaction with Dynamin3
ABSTRACT
Cholangiocarcinoma (abbreviated as CCA) accounts for about 3% of digestive tract tumors, which is a rare disease with relatively low incidence. Herein, we firstly discovered overexpression of microRNA-23a-3p (abbreviated as miR-23a-3p) in CCA tissues, as well as cell lines via bioinformatics prediction. Next, by conducting miR-23a-3p knockdown system in HUCCT1 cells and miR-23a-3p overexpression system in RBE cells, we investigated the biological effects of miR-23a-3p. Based on our findings, inhibition of miR-23a-3p was able to prevent cancer cell proliferation via colony formation, CCK-8, as well as EdU assays. Moreover, invasion as well as migration abilities of cells was examined by transwell assay and wound healing test. Animal study further verified that knockdown miR-23a-3p slowed down tumor growth and lung metastasis. In addition, we identified cholangiocarcinoma cells transferred miR-23a-3p through exosomes by a series of assays. Functional experiments have confirmed that exosomal miR-23a-3p could benefit for cancer cell growth and metastasis, serving as a cancer promoting gene. Furthermore, we found Dynamin3 (abbreviated as DNM3) turned out to be a target of miR-23a-3p, while DNM3 was down-regulated in cholangiocarcinoma. Knockdown DNM3 accelerated cancer cell development. Collectively, our findings firstly pointed out that exosomal miR-23a-3p was conducive to the progression of cholangiocarcinoma by interaction with DNM3, which provided potential evidence for cancer treatment.